Scientific Publications

SomaLogic is committed to rapid publication of our scientific findings in the peer-reviewed literature.

Below is a chronological list of select articles by SomaLogic scientists and their collaborators.

Download an annotated publications list that includes articles from users of SomaLogic’s proteomic technology.


Genomic atlas of the human plasma proteome (2018) BB Sun, JC Maranville, JE Peters, D Stacey, JR Staley, J Blackshaw, S Burgess, T Jiang, E Paige, P Surendran, C Oliver-Williams, MA Kamat, BP Prins, SK Wilcox, ES Z, A Chi, N Bansal, SL Spain, AM Wood, NW Morrell, JR Bradley, N Janjic, DJ Roberts, WH Ouwehand, JA Todd, N Soranzo, K Suhre, DS Paul, CS Fox, RM Plenge, J Danesh, H Runz, and AS Butterworth.
Nature 558: 73-79 (SUBSCRIPTION REQUIRED).

Sperm cell purification from mock forensic swabs using SOMAmer™ affinity reagents (2018) E Katilius, AB Carmel, H Koss, D O’Connell, BC Smith, GM Sanders, GS LaBerge.
Forensic Science International: Genetics 35:9-13 (SUBSCRIPTION REQUIRED).

The impact of the glomerular filtration rate on the human plasma proteome (2018) A Christensson, JA Ash, RK DeLisle, FW Gaspar, R Ostroff, A Grubb, V Lindström, L Bruum, and SA Williams.
Proteomics Clinical Applications 12(3): e1700067 (SUBSCRIPTION REQUIRED).

Improving assessment of drug safety through proteomics: early detection and mechanistic characterization of the unforeseen harmful effects of torcetrapib (2018) SA Williams, AC Murthy, RK DeLisle, C Hyde, A Malarstig, R Ostroff, SJ Weiss, MR Segal, and P Ganz. 
Circulation 137(10) 999-1010.

Also see accompanying editorial:
Harnessing the power of proteomics to assess drug safety and guide clinical trials (2018) MPY Lam and Y Ge.
Circulation 137(10) 1011-1014 (SUBSCRIPTION REQUIRED).


Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease (2017) TJ Scriba, A Penn-Nicholson, S Shankar, T Hraha, EG Thompson, D Sterling, E Nemes, F Darboe, S Suliman, LM Amon, H Mahomed, M Erasmus, W Whatney, JL Johnson, W Boom, M Hatherill, J Valvo, MA De Groote, UA Ochsner, A Aderem, WA Hanekom, DE Zak, and other members of the ACS cohort study team.
PLOS Pathogens 13(11): e1006687.

Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation (2017) KD Sullivan, D Evans, A Pandey, TH Hraha, KP Smith, N Markham, AL Rachubinski, K Wolter-Warmerdam, F Hickey, JM Espinosa, and T Blumenthal.
Scientific Reports 7: 14818.

Pharmacokinetic properties of DNA aptamers with base modifications (2017) S Gupta, DW Drolet, SK WolkSM Waugh, JC Rohloff, JD Carter, WS Mayfield, MR Otis, CR Fowler, T Suzuki, M Hirota, Y Ishikawa, DJ Schneider, and N Janjic.
Nucleic Acid Therapeutics 27(6):345-353.

Structural basis for IL-1α recognition by a modified DNA aptamer that specifically inhibits IL-1α signaling (2017) X Ren, AD Gelina, I von Carlowitz, N Janjic, and AM Pyle. 
Nature Communications 8(1) 810.

Discovery of a six-marker serum protein signature for the diagnosis of pulmonary tuberculosis (2017) MA De Groote, DG Sterling, T Hraha, T Russell, LS Green, K Wall, S Kraemer, R Ostroff, N Janjic, and UA Ochsner. 
Journal of Clinical Microbiology 55(10) 3057-3071.

Potential of high-affinity, Slow Off-Rate Modified Aptamer (SOMAmer) reagents for Mycobacterium tuberculosis proteins as tools for infection models and diagnostic applications (2017) T Russell, LS Green, T Rice, NA Kruh-Garcia, K Dobos, MA De Groote, T Hraha, DG Sterling, N Janjic, and UA Ochsner.
Journal of Clinical Microbiology 55(10) 3072-3088.

Selection of DNA aptamers with two modified bases (2017) BN Gawande, JC Rohloff, JD Carter, I von Carlowitz, C Zhang, DJ Schneider, and N Janjic.
Proceedings of the National Academy of Sciences 114(11):2898-2903.

Connecting genetic risk to disease end points through the human blood plasma proteome (2017) K Suhre, M Arnold, AM Bhagwat, RJ Cotton, R Engelke, J Raffler, H Sarwath, G Thareja, A Wahl, RK DeLisle, L Gold, M Pezer, G Lauc, MA El-Din Selim, DO Mook-Kanamori, EK Al-Dous, YA Mohamoud, J Malek, K Strauch, H Grallert, A Peters, G Kastenmüller, C Gieger, and J Graumann.
Nature Communications 8:14357.

Highly multiplexed proteomic analysis of quantiferon supernatants to identify biomarkers of latent tuberculosis infection (2017) MA De Groote, M Higgins, T Hraha, K Wall, ML Wilson, DG Sterling, N Janjic, R Reves, UA Ochsner, and R Belknap.
Journal of Clinical Microbiology 55:391-402.


Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease (2016) PJ Ganz, B Heidecker, K Hveem, C Jonasson, S Kato, MR Segal, DG Sterling, and SA Williams.
Journal of the American Medical Association 315(23):2532-2541.

Also see accompanying editorial:  
Using aptamer-based technology to probe the plasma proteome for cardiovascular Disease prediction (2016) M Sabatine.
Journal of the American Medical Association 315(23):2525-2526. (SUBSCRIPTION REQUIRED). For access to electronic version, please contact us.

Chemically modified interleukin-6 aptamer inhibits development of collagen-induced arthritis in cynomolgus monkeys (2016) M Hirota, I Murakami, Y Ishikawa, T Suzuki, S Sumida, S Ibaragi, H Kasai, N Horai, DW Drolet, S Gupta, N Janjic, and DJ Schneider.
Nucleic Acid Therapeutics 26(1):10-19.

Embracing proteins: structural themes in aptamer-protein complexes (2016) AD Gelinas, DR Davies and N Janjic.
Current Opinion in Structural Biology 36:122-32.

Fit for the eye: aptamers in ocular disorders (2016) DW Drolet, LS Green, L Gold and N Janjic.
Nucleic Acid Therapeutics 26(3) 127-146. 


Influence of 5-N-carboxamide modifications on the thermodynamic stability of oligonucleotides (2015) SK Wolk, RK Shoemaker, WS Mayfield, AL Mestdagh and N Janjic.
Nucleic Acids Research 43(19):9107-9122.

Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts (2015) KA Olson, AL Beatty, B Heidecker, MC Regan, EN Brody, T Foremen, S Kato, RE Mehler, BS Singer, K Hveem, H Dalen, DG Sterling, RM Lawn, NB Schiller, SA Williams, MA Whooley, and P Ganz.
European Heart Journal 36(48):3426-3434.

Practical synthesis of cytidine-5-carboxamide-modified nucleotide reagents (2015) JC Rohloff, C Fowler, B Ream, JD Carter, G Wardle and T Fitzwater.
Nucleosides Nucleotides and Nucleic Acids 34(3):180-198.

Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy (2015) Y Hathout, E Brody, PR Clemens, L Cripe, RK DeLisle, P Furlong, H Gordish-Dressman, L Hache, E Henricson, EP Hoffman, YM Kobayashi, A Lorts, JK Mah, C McDonald, B Mehler, S Nelson, M Nikrad, B Singer, F Steele, D Sterling, HL Sweeney, S Williams and L Gold.
Proceedings of the National Academy of Sciences USA 112(23):7153-7158.

Non-helical DNA triplex forms a unique aptamer scaffold for high affinity recognition of nerve growth factor (2015) TC Jarvis, DR Davies. A Hisaminato, DI Resnicow, S Gupta, SM Waugh, A Nagabukuro, T Wadatsu, H Hishigaki, B Gawande, C Zhang, SK Wolk, WS Mayfield, Y Nakaishi, AB Burgin, LJ Stewart, TE Edwards, AD Gelinas, DJ Schneider and N Janjic.
Structure 23(7):1293-1304. 

Circulating proteomic signatures of chronological age (2015) C Menni, SJ Kiddle, M Mangino, A Viñuela, M Psatha, C Steves, M Sattlecker, A Buil, S Newhouse, S Nelson, S Williams, N Voyle, H Soininen, I Kloszewska, P Mecocci, M Tsolaki, B Vellas, S Lovestone, TD Spector, R Dobson and AM Valdes.
Journal of Gerontology: Series A, Biological Sciences and Medical Sciences 70(7):809-816.


Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents (2014) JC Rohloff, AD Gelinas, TC Jarvis, UA Ochsner, DJ Schneider, L Gold and N Janjic.
Molecular Therapy Nucleic Acids 3(10):e201.

Specific capture and detection of Staphylococcus aureus with high-affinity modified aptamers to cell surface components (2014) A Baumstummler, D Lehmann, N Janjic and UA Ochsner.
Letters in Applied Microbiology 59(4):422-431.

Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis (2014) P Nahid, E Bliven-Sizemore, LG Jarlsberg, MA De Groote, JL Johnson, G Muzanyi, M Engle, M Weiner, N Janjic, DG Sterling and UA Ochsner.
Tuberculosis 94(3):187-196. 

Validation of a blood protein signature for non-small cell lung cancer (2014) M Mehan, SA Williams, JM Siegfried, WL Bigbee, JL Weissfeld, DO Wilson, HI Pass, WN Rom, T Muley, M Meister, W Franklin, YE Miller, EN Brody and RM Ostroff.
Clinical Proteomics 11(1):32.

Alzheimer’s disease biomarker discovery using SOMAscan multiplexed protein technology (2014) M Sattlecker, SJ Kiddle, S Newhouse, P Proitsi, S Nelson, S Williams, C Johnston, R Killick, A Simmons, E Westman, A Hodges, H Soininen, I Kloszewska, P Mecocci, M Tsolaki, B Vellas, S Lovestone, AddNeuroMed Consortium and RJ Dobson.
Alzheimer’s & Dementia 10(6):724-734.

Systematic selection of modified aptamer pairs for diagnostic sandwich assays (2014) UA Ochsner, LS Green, L Gold and N Janjic.
Biotechniques 56(3):125-133.

Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscan™) platform (2014) J Webber, TC Stone, E Katilius, BC Smith, B Gordon, MD Mason, Z Tabi, IA Brewis and A Clayton.
Molecular & Cellular Proteomics 13(4):1050-1064.

DTC-and-me: patient, provider, proteins and regulators (2014) F Steele and L Gold.
Journal of Personalized Medicine 4(1):79-87.

Beyond antibodies: new affinity reagents to unlock the proteome (2014) B Lollo, F Steele and L Gold.
Proteomics 14:638-644.

Crystal structure of interleukin-6 in complex with a modified nucleic acid ligand (2014) AD Gelinas, DR Davies, TE Edwards, JC Rohloff, JD Carter, C Zhang, S Gupta, Y Ishikawa, M Hirota, Y Nakaishi, TC Jarvis and N Janjic.
Journal of Biological Chemistry 289(12):8720-8734.

Chemically-modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor (2014) S Gupta, M Hirota, SM Waugh, I Murakami, T Suzuki, M Muraguchi, M Shibamori, Y Ishikawa, TC Jarvis, JD Carter, C Zhang, B Gawande, M Vrkljan, N Janjic and DJ Schneider.
Journal of Biological Chemistry 289(12):8706-8719.


Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy (2013) FS Loffredo, ML Steinhauser, SM Jay, J Gannon, JR Pancoast, P Yalamanchi, M Sinha, C Dall’Osso, D Khong, JL Shadrach, CM Miller, BS Singer, A Stewart, N Psychogios, RE Gerszten, AJ Hartigan, MJ Kim, T Serwold, AJ Wagers and RT Lee.
Cell 153(4):829-839.

Measurement of cetuximab and panitumumab-unbound serum EGFR extracellular domain using an assay based on Slow Off-Rate Modified Aptamer (SOMAmer) reagents (2013) NJ Park, X Wang, A Diaz, DM Goos-Root, C Bock, JD Vaught, W Sun and CM Strom.
PLOS ONE (2013) 8(8):e71703.

Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment (2013) MA De Groote, P Nahid, L Jarlsberg, JL Johnson, M Weiner, G Muzanyi, N Janjic, DG Sterling and UA Ochsner.
PLOS ONE 8(4):e61002. 

Interaction with both ZNRF3 and LGR4 is required for the signaling activity of R-spondin (2013) Y Xie, R Zamponi, O Charlat, M Ramones, S Swalley, X Jiang, D Rivera, W Tschatz, B Lu, L Quinn, C Dimitri, J Parker, D Jeffery, SK Wilcox, M Watrobka, P LeMotte, B Granda, JA Porter, VE Myer, A Loew, and F Cong.
EMBO Reports 14(12):1120-1126.

Taking measure of personalized medicine: the proteome (2013) F Steele and L Gold.
Personalized Medicine 10(2): 177-182. (For reprint contact

Candidate blood proteome markers of Alzheimer’s disease onset and progression: a systematic review and replication study (2013) SJ Kiddle, M Sattlecker, P Proitsi, A Simmons, E Westman, C Bazenet, SK Nelson, S Williams, A Hodges, C Johnston, H Soininen, I Kloszewska, P Mecocci, M Tsolaki, B Vellas, S Newhouse, S Lovestone and RJ Dobson.
Journal of Alzheimers Disease 38(3):515-531.

Detection of Clostridium difficile toxins A, B, and binary toxin with slow off-rate modified aptamers (2013) UA Ochsner, E Katilius and N Janjic.
Diagnostic Microbiology and Infectious Disease 76(3):278-285. (SUBSCRIPTION REQUIRED)


Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool (2012) RM Ostroff, MR Mehan, A Stewart, D Ayers, EN Brody, SA Williams, S Levin, B Black, M Harbut, M Carbone, C Goparaju and HI Pass.
PLOS ONE 7(10): e46091.

Life’s simple measures: unlocking the proteome (2012) E Brody, L Gold, M Mehan, R Ostroff, J Rohloff, J Walker and D Zichi.
Journal of Molecular Biology 422(5):595-606. (SUBSCRIPTION REQUIRED).

Slow Off-Rate Modified Aptamer arrays for biomarker discovery and diagnostic applications (2012) JJ Walker, EN Brody, and L Gold.
In Microarrays in Diagnostics and Biomarker Development.” (Ed: B Jordan) Springer, ISBN 978-3-642-28202-7. (SUBSCRIPTION REQUIRED).

Protein signature of lung cancer tissues (2012) MR Mehan, D Ayers, D Thirstup, W Xiong, RM Ostroff, EN Brody, JJ Walker, L Gold, TC Jarvis, N Janjic, GS Baird and SK Wilcox.
PLOS ONE 7(4):e35157.

Age-dependent changes in the cerebrospinal fluid proteome by Slow Off-Rate Modified Aptamer array (2012) GS Baird, SK Nelson, TR Keeney, A Stewart, S Williams, ER Peskind and TJ Montine.
American Journal of Pathology 180(2):446-456.

Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets (2012) DR Davies, AD Gelinas, C Zhang, JC Rohloff, JD Carter, D O’Connell, SM Waugh, SK Wolk, WS Mayfield, AB Burgin, TE Edwards, LJ Stewart, L Gold, N Janjic and TC Jarvis.
Proceedings of the National Academy of Sciences USA 109(49): 19971-19976.


From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay (2011) S Kraemer, JD Vaught, C Bock, L Gold, E Katilius, TR Keeney, N Kim, NA Saccamano, SK Wilcox, D Zichi and GM Sanders.
PLOS ONE 6(10): e26332. 

Making the cut: untangling clinical protein biomarker discovery and validation (2011) L Gold, S Williams, N Janjic, N Saccomano and F Steele.
Biomarkers in Medicine 5(2):189-191.

Rapid histochemistry using Slow Off-rate Modified Aptamers with anionic competition. (2011) S Gupta, D Thirstrup, TC Jarvis, DJ Schneider, SK Wilcox, J Carter, C Zhang, A Gelinas, A Weiss, N Janjic and GS Baird.
Applied Immunohistochemistry & Molecular Morphology 19(3):273-8. (SUBSCRIPTION REQUIRED).


High-Content Affinity-Based Proteomics: Unlocking Protein Biomarker Discovery (2010) EN Brody, L Gold, RM Lawn, JJ Walker, and D Zichi.
Expert Review of Molecular Diagnostics 10(8):1013-1022.

Aptamers and the RNA world, past and present (2010) L Gold, N Janjic, T Jarvis, DD Schneider, JJ Walker, SK Wilcox and D Zichi.
Cold Spring Harbor Perspectives in Biology 4(3):a003582.

Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer (2010) RM Ostroff, WL Bigbee, W Franklin, L Gold, M Mehan, YE Miller, HI Pass, WN Rom, JM Siegfried, A Stewart, JJ Walker, JL Weissfeld, SA Williams, D Zichi, EN Brody.
PLOS ONE 5(12):e15003. 

Expanding the chemistry of DNA for in vitro selection (2010) JD Vaught, C Bock, J Carter, T Fitzwater, M Otis, D Schneider, J Rolando, S Waugh, SK Wilcox and B Eaton.
Journal of the American Chemical Society 132(12):4141–4151. (SUBSCRIPTION REQUIRED).

The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array. (2010) R Ostroff, T Foreman, TR Keeney, S Stratford, JJ Walker and D Zichi.
Journal of Proteomics 73(3):649-66. (SUBSCRIPTION REQUIRED).

Aptamer-based multiplexed proteomic technology for biomarker discovery (2010) L Gold, D Ayers, J Bertino, C Bock, A Bock, EN Brody, J Carter, AB Dalby, BE Eaton, T Fitzwater, D Flather, A Forbes, T Foreman, C Fowler, B Gawande, M Goss, M Gunn, S Gupta, D Halladay, J Heil, J Heilig, B Hicke, G Husar, N Janjic, T Jarvis, S Jennings, E Katilius, TR Keeney, N Kim, TH Koch, S Kraemer, L Kroiss, N Le, W Lindsey, B Lollo, W Mayfield, M Mehan, R Mehler, M Nelson, SK Nelson, D Nieuwlandt, M Nikrad, U Ochsner, RM Ostroff, M Otis, T Parker, S Pietrasiewicz, DI Resnicow, J Rohloff, G Sanders, S Sattin, D. Schneider, B Singer, M Stanton, A Sterkel, A Stewart, S Stratford, JD Vaught, M Vrkljan, JJ Walker, M Watrobka, S Waugh, A Weiss, SK Wilcox, A Wolfson, SK Wolk, C Zhang and D Zichi.
PLOS ONE 5(12):e15004. 


Proteomics and diagnostics: let’s get specific, again (2008) D Zichi, B Eaton, B Singer and L Gold.
Current Opinion in Chemical Biology 12(1):78–85. (SUBSCRIPTION REQUIRED).

Aptamers: the new frontier in drug development? (2007) B Carlson.
Biotechnology Healthcare 4(2):31-36. 

Aptamers as therapeutic and diagnostic agents (2000) EN Brody and L Gold.
Reviews in Molecular Biotechnology 74(1):5-13. (SUBSCRIPTION REQUIRED).

High affinity ligands from in vitro selection: complex targets. (1998) KN Morris, KB Jensen, CM Julin, M Weil, and L Gold.
Proceedings of the National Academy of Sciences USA 95(6):2902-2907.

Let’s get specific: The relationship between specificity and affinity (1995) BE Eaton, L Gold and DA Zichi.
Chemistry & Biology 2(10):633-638.

Systematic evolution of ligands by exponential enrichment: RNA Ligands to bacteriophage T4 DNA polymerase (1990) C Tuerk and L Gold.
Science 249(4968):505-510. (SUBSCRIPTION REQUIRED).